不同MET瘤改变对I型和II型MET抑制剂的反应性
Yonina R Murciano-Goroff1, Valentina Foglizzo2,3, Jason Chang4
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Clinical and translational medicine
|May 29, 2025
概括
在有固体瘤的患者中发现了新的MET耐药突变. 二型氨酸激酶抑制剂 (TKIs) 对这些突变显示出有效性,指导针对MET改变癌症的向治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在c-MET受体氨酸激酶 (MET) 中的突变驱动癌症或赋予治疗耐药性.
- 甲状腺氨酸激酶抑制剂 (TKI) 分为I型 (DFG-in) 或II型 (DFG-out).
- 了解TKI类对各种MET变化的影响对于优化癌症治疗至关重要.
研究的目的:
- 为了描述新的MET耐药性突变.
- 评估各种MET修改对I型和II型技术知识产权的反应.
- 评估II型TKI在MET突变癌症患者的临床疗效.
主要方法:
- 使用了结构建模,体外激酶试验和基于细胞的试验.
- 临床前发现被转化为患者治疗.
- 选择的MET抑制剂被用于MET突变瘤患者.
主要成果:
- 在患有固体瘤的患者中发现了四种MET耐药突变 (三种新瘤),其中一些患者先前接受了I型TKI治疗.
- 在和生化分析中,II型TKIs (cabozantinib/foretinib) 保留了对新型MET突变 (METG1090A,METY1230S) 的活性,与I型TKIs不同.
- 两名患有非小细胞肺癌和细胞癌的患者,患有未表征的MET变异,对卡博赞提尼布治疗有反应.
结论:
- 对TKI类的突变敏感性的全面描述可以指导临床干预.
- 可优化向疗法,以克服MET改变癌症的耐药性.
- 针对TKI类的激酶突变的生物化学分析对于明智的临床决策至关重要.
相关概念视频
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K


